ASSET
Acute Lymphoblastic Leukaemia Sub-Types and Side Effects from Treatment (ASSET) Study
The Acute Lymphoblastic Leukaemia Sub-Types and Side Effects from Treatment (ASSET) Study aims to further our understanding into how treatment-related toxicities affect all aspects of health-related quality of life of children with Acute Lymphoblastic Leukaemia and their families.
Contact the Principal Investigator Dr Joanna Fardell or Study Coordinator, Dr Clarissa Schilstra for questions about this study.
Publications
Fardell, J. E., Vetsch, J., Trahair, T., Mateos, M., Grootenhuis, M., Touyz, L., Marshall, G., & Wakefield, C. (2017). Health‐related quality of life of children on treatment for acute lymphoblastic leukemia: a systematic review. PEDIATRIC BLOOD & CANCER, 64(9), e26489.
Schilstra, C. E., McCleary, K., Fardell, J. E., Donoghoe, M. W., McCormack, E., Kotecha, R. S., Lourenco, R. D. A., Ramachandran, S., Cockcroft, R., & Conyers, R. (2022). Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia. BMC cancer, 22(1), 985.
